Supplementary Table 3. Propensity matched analysis

Variable	OR (95% CI)	*P*-value
Model: propensity matching only		
Outcome: DRO development		
Rifaximin on admission	1.05 (0.78–1.42)	0.758
Outcome: composite death or DRO		
Rifaximin on admission	1.33 (1.06–1.67)	0.012
Model: propensity matching+double adjustment*		
Outcome: DRO development		
Rifaximin on admission	1.02 (0.74–1.40)	0.918
HBV etiology	0.50 (0.26–0.88)	0.023
PPI on admission	0.70 (0.51–0.96)	0.029
Outcome: composite death or DRO		
Rifaximin on admission	1.16 (0.90–1.48)	0.253
Low income (vs. High)	2.00 (1.46–2.74)	<0.001
UMI income (vs. High)	1.75 (1.28–2.40)	<0.001
Prior HE	1.31 (1.02–1.69)	0.038
MELD-Na	1.06 (1.05–1.08)	<0.001

CI, confidence interval; DRO, drug-resistant organism; HBV, hepatitis B virus; HE, hepatic encephalopathy; MELD-Na, Model for end-stage liver disease; PPI, proton pump inihibitor; OR, odds ratio; SMD, standardized mean difference; UMI, upper-middle income.
*As shown in Supplementary Table 2, all variables $P<0.05$ or SMD>0.1 after matching.

 https://doi.org/10.3350/cmh.2026.0228